Organon & Co.OGNEarnings & Financial Report
NYSE · Health Care · Pharmaceutical Preparations
Organon & Co. is an American pharmaceutical company headquartered in Jersey City, New Jersey. Organon specializes in the following core therapeutic fields: reproductive medicine, contraception, psychiatry, hormone replacement therapy (HRT), and anesthesia. Organon produces all its products outside of the United States but receives a third of its revenue from the United States.
Top Holders
| Holder | % Owned | Shares | Change | As of |
|---|---|---|---|---|
| BlackRock, Inc. | 13.10% | 33.5M | ▲ +0.40pp | 2024-01-23 |
| The Vanguard Group | 11.97% | 30.6M | — | 2024-02-13 |
| STATE STREET CORPORATION | 3.72% | 68.6K | — | 2024-01-25 |
| NOS. OF ABOVE PERSONS | 0.00% | 255.6M | — | 2024-02-05 |
Insider Transactions
Net 90d: +$0 · buys $0 / sells $0Range:
Action:
Role:
| Insider | Role | Action | ||||
|---|---|---|---|---|---|---|
| 2026-03-31 | WALSH MATTHEW M | Chief Financial Officer | Option exercise | 12.0K | $0.00 | $0 |
| 2026-03-31 | WALSH MATTHEW M | Chief Financial Officer | Option exercise | 21.5K | $0.00 | $0 |
| 2026-03-31 | Stahler Rachel A | Chief Information Officer | Option exercise | 6.6K | $0.00 | $0 |
| 2026-03-31 | Stahler Rachel A | Chief Information Officer | Option exercise | 12.3K | $0.00 | $0 |
| 2026-03-31 | Daniel Karp | Executive VP, Corp. Dev. | Option exercise | 11.3K | $0.00 | $0 |
| 2026-03-31 | Daniel Karp | Executive VP, Corp. Dev. | Option exercise | 6.7K | $0.00 | $0 |
| 2026-03-31 | Drinane Juliana Papa | Interim Head of Mfg & Supply | Option exercise | 6.4K | $0.00 | $0 |
| 2026-03-31 | Drinane Juliana Papa | Interim Head of Mfg & Supply | Option exercise | 10.1K | $0.00 | $0 |
| 2026-03-31 | Arjona Ferreira Juan Camilo | Head of R&D & CMO | Option exercise | 13.4K | $0.00 | $0 |
| 2026-03-31 | Aaron Falcione | Chief Human Resources Officer | Option exercise | 6.7K | $0.00 | $0 |
1–10 of 41
Page 1 / 5